AngioDynamics, Inc. (NASDAQ:ANGO – Get Free Report) has earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is $19.3333.
A number of equities research analysts have recently weighed in on the stock. Wall Street Zen lowered shares of AngioDynamics from a “buy” rating to a “hold” rating in a report on Sunday, December 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, January 21st. Finally, Zacks Research raised AngioDynamics from a “hold” rating to a “strong-buy” rating in a report on Friday, January 9th.
Get Our Latest Stock Analysis on ANGO
Institutional Trading of AngioDynamics
AngioDynamics Price Performance
Shares of NASDAQ ANGO opened at $10.90 on Friday. The company has a market cap of $449.30 million, a price-to-earnings ratio of -16.27 and a beta of 0.48. The stock’s 50-day moving average is $10.80 and its two-hundred day moving average is $11.54. AngioDynamics has a 1-year low of $8.36 and a 1-year high of $13.99.
About AngioDynamics
AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.
In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.
Recommended Stories
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.
